Microspheres
Reduce dosing frequency with release tuned from one week to 12 months
Encapsulate your API in biodegradable lipid microspheres that release it at a controlled rate, so each dose lasts longer and treatment is easier to give. License the technology and develop your product with one team, from feasibility to commercial supply.
Talk to our formulation scientists
1 week to 12 months of tunable sustained release
34% drug loading achieved for a controlled-release injectable
<1,000 µm diameter for standard needle and syringe injection
How It Works
Each microsphere is a solid lipid particle with your API, in amorphous or crystalline form, dispersed through a biodegradable wax matrix. The particles are large enough to flow freely and handle easily during manufacture, and small enough to be injected through a conventional needle and syringe.
Once administered, the lipid matrix resorbs and releases your API at a controlled rate, keeping plasma concentrations steady for far longer than an immediate-release dose.
Tune release from 1 week to 12 months by adjusting microsphere size and lipid matrix composition, or by adding pore formers or surfactants, so you give fewer doses and cause the animal less stress.
Raise the bioavailability of poorly water-soluble drugs by dissolving them in lipids and converting the API from a crystalline to a stable amorphous form.
Subcutaneous injection bypasses first-pass metabolism, so you can achieve efficacy with smaller doses and make the most of your API.
Encapsulating your API in a solid lipid matrix reduces its release in the mouth and its contact with taste buds, making oral medicines more palatable and easier to administer.
At under 1,000 µm, microspheres pass through a standard needle and syringe, so you avoid the large-gauge needles or surgical insertion that polymeric implants typically need.
Biocompatible materials make microspheres less susceptible to injection-site reactions and immune responses, thereby supporting a safer product profile.
Microspheres work with almost any API, from small lipophilic molecules to peptides. However, lipid microspheres aren’t suitable for thermolabile APIs.
Use microspheres across therapeutic classes, including antiparasitics, analgesics, and anti-inflammatories for skin diseases such as atopic dermatitis.
Subcutaneous injections and oral dosage forms.
Companion and production animals, including dogs, cats, horses, cattle, swine, sheep, and goats.
Manufacturing
Take your microsphere product from development to commercial manufacture with one of the few organisations globally equipped to do it for animal health.
Confirm feasibility, drug loading, and API and excipient compatibility before you make a significant investment.
Optimise microsphere composition for extended release, taste masking, or enhanced bioavailability.
Run pharmacokinetic, safety, and efficacy studies at our own clinical sites in the US and UK, with healthy and diseased animal models.
Build your regulatory strategy with a team that specialises in animal health and understands the regulations for microsphere-based products.
Scale and validate your microsphere process from GMP clinical batches to commercial manufacture.
Manufacture at commercial scale in our ready-built microsphere infrastructure.
